| Drug General Information |
| Drug ID |
D0SM0J
|
| Former ID |
DNC003766
|
| Drug Name |
LY-117018
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C27H25NO4S
|
| Canonical SMILES |
C1CCN(C1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=<br />CC=C(C=C5)O
|
| InChI |
1S/C27H25NO4S/c29-20-7-3-19(4-8-20)27-25(23-12-9-21(30)17-24(23)33-27)26(31)18-5-10-22(11-6-18)32-16-15-28-13-1-2-14-28/h3-12,17,29-30H,1-2,13-16H2
|
| InChIKey |
JLERVPBPJHKRBJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Estrogen receptor beta |
Target Info |
Inhibitor |
[2]
|
|---|
| Estrogen receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
Reactome
|
Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Integrated Pancreatic Cancer Pathway
|
|
Nuclear ReceptorsWP712:Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000893) |
|---|
| REF 2 | J Med Chem. 1990 Dec;33(12):3222-9.Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. |
|---|
